<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898077</url>
  </required_header>
  <id_info>
    <org_study_id>15244</org_study_id>
    <secondary_id>I4T-CR-JVCR</secondary_id>
    <nct_id>NCT02898077</nct_id>
  </id_info>
  <brief_title>A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab
      in participants with gastric and gastroesophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to Date of Death from Any Cause (Approximately 12 Months)</time_frame>
    <description>OS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Approximately 4 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Randomization to the Date of the First Radiographically Documented Progressive Disease (Approximately 4 Months)</time_frame>
    <description>TTP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with a Best Overall Response (BOR) of Partial Response (PR) or Complete Response (CR)</measure>
    <time_frame>Randomization to Objective Disease Progression (Approximately 4 Months)</time_frame>
    <description>ORR: Percentage of participants with a BOR of PR or CR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Approximately 4 Months)</time_frame>
    <description>Duration of objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 30 Days After Treatment Discontinuation (Approximately 4 Months)</time_frame>
    <description>Change from baseline on the EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the EuroQol-5 Dimension-3 Level Questionnaire (EQ-5D-3L)</measure>
    <time_frame>Baseline, 30 Days After Treatment Discontinuation (Approximately 4 Months)</time_frame>
    <description>Change from Baseline on the EQ-5D-3L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab intravenously (IV) on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo IV on days 1 and 15 every 28-day cycle. Paclitaxel IV on days 1, 8, and 15 of every 28-day cycle. Participants will continue treatment until discontinuation criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab + Paclitaxel</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo + Paclitaxel</arm_group_label>
    <arm_group_label>Ramucirumab + Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo + Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 or 1 at
             study entry.

          -  Have a histopathologically or cytologically confirmed diagnosis of gastric or
             gastroesophageal junction (GEJ) adenocarcinoma.

          -  Have metastatic disease or locally advanced, unresectable disease.

          -  Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid
             Tumors (RECIST), Version 1.1.

          -  Have experienced documented objective radiographic or symptomatic disease progression
             during first-line therapy, or within 4 months after the last dose of first-line
             therapy with any platinum/fluoropyrimidine doublet for unresectable or metastatic
             disease.

          -  Have adequate organ function.

          -  Have urinary protein ≤1+ on dipstick or routine urinalysis.

        Exclusion Criteria:

          -  Have undergone major surgery within 28 days prior to randomization.

          -  Have received any first-line chemotherapy other than platinum and fluoropyrimidine
             with or without anthracycline for advanced gastric or GEJ adenocarcinoma.

          -  Have received any previous systemic therapy (including investigational agents)
             targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signaling
             pathways.

          -  Have a history of deep vein thrombosis, pulmonary embolism, or any other significant
             thromboembolism during the 3 months prior to randomization.

          -  Have significant bleeding disorders, vasculitis, or had a significant bleeding episode
             from the gastrointestinal (GI) tract within 3 months prior to study entry.

          -  Have a history of GI perforation and/or fistulae within 6 months prior to
             randomization.

          -  Have experienced any arterial thromboembolic event within 6 months prior to
             randomization.

          -  Have uncontrolled arterial hypertension (systolic blood pressure ≥160 millimeters of
             mercury [mmHg] or diastolic blood pressure ≥100 mmHg) despite standard medical
             management.

          -  Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days
             prior to randomization.

          -  Have a serious illness or medical condition(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Fifth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital affiliated to Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Han Tongji Hospital</name>
      <address>
        <city>Wuhan City</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union (Xiehe) Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Province Tumor Hospital</name>
      <address>
        <city>Chang Chun</city>
        <state>Ji Lin</state>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nan Jing No. 81 Hospital</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiang Su</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tang Du Hospital, The Second Teaching Hospital of FMMU</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical &amp; Dental Institute HUSM</name>
      <address>
        <city>Kepala Batas, Pulau Pinang</city>
        <zip>13200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Wilayah Persekutuan</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors Hospital</name>
      <address>
        <city>Cebu City</city>
        <state>Cebu</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Pablo O. Torre Memorial Hospital</name>
      <address>
        <city>Bacolod</city>
        <zip>6100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>De La Salle Health Sciences Institute</name>
      <address>
        <city>Cavite City</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Bangkok</city>
        <state>Ratchathewi District</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memoiral Hospsital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Police General Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Muang, Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Second line</keyword>
  <keyword>Angiogenesis</keyword>
  <keyword>Vascular endothelial growth factor receptor 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

